ErbB3 Mouse

Tyrosine Kinase ErbB-3, also known as HER3, is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This protein plays a crucial role in cellular signaling pathways that regulate cell proliferation, differentiation, and survival. The recombinant form of ErbB-3, particularly from mouse models, is widely used in research to understand its function and role in various diseases, including cancer.

ErbB-3 is a membrane-bound protein that contains a neuregulin binding domain but lacks an active kinase domain . This means that while it can bind to its ligand, it cannot convey the signal into the cell through protein phosphorylation on its own. Instead, ErbB-3 forms heterodimers with other members of the EGFR family, such as ErbB-2 (HER2), which possess kinase activity . This heterodimerization leads to the activation of downstream signaling pathways that promote cell proliferation and differentiation .

ErbB-3 is expressed in various tissues, including epithelial tissues and the brain . Its expression is tightly regulated, and dysregulation can lead to pathological conditions. Overexpression or amplification of the ErbB-3 gene has been reported in numerous cancers, including prostate, bladder, and breast tumors . This overexpression is often associated with poor prognosis and resistance to certain therapies.

Recombinant ErbB-3 proteins, particularly those derived from mouse models, are invaluable tools in biomedical research. These proteins are typically produced in expression hosts such as HEK293 cells and purified to high levels of purity . Researchers use recombinant ErbB-3 to study its biochemical properties, interaction with other proteins, and role in signaling pathways. Additionally, recombinant ErbB-3 is used in drug discovery and development to screen for potential therapeutic agents that target this receptor.

The study of ErbB-3 has significant clinical implications. Given its role in cancer progression, ErbB-3 is a potential target for cancer therapies. Understanding the mechanisms by which ErbB-3 contributes to tumor growth and resistance to treatment can lead to the development of novel therapeutic strategies. For instance, therapies that disrupt the interaction between ErbB-3 and its heterodimer partners or inhibit its downstream signaling pathways are being explored as potential cancer treatments.